Response to Comments: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (DL39040)

This A59116 document is a response-to-comments notice and notes a title revision for MolDX LCD DL39040. It does not contain substantive coverage criteria; the detailed coverage policy for lab-developed tests for inherited cancer syndromes in patients with cancer is in LCD DL39040, effective 2022-07-03, and should be consulted for indications, limitations, documentation, and frequency rules.

"This document is a response to comments and does not itself define coverage; refer to MolDX LCD DL39040 (effective 2022-07-03) for the full coverage criteria for lab-developed tests for inherited c..."

Sign up to see full coverage criteria, indications, and limitations.